


Immune-Related Adverse Event: Arthralgia/Myalgia

Arthralgia is an increasingly recognised side effect of oncological immunotherapy. This may manifest with single joint involvement or multi-articular involvement with synovitis. Additionally patients may develop myalgia which may go on to develop myositis. It is important to note that myositis can evolve into myocarditis and thus it is important to undertake the investigations recommended and monitor both symptomatic and biochemical responses to treatment. Patients often require non-steroid sparing agents so please implement the protocols for management of patients on these agents eg methotrexate and consider early referral to local rheumatology services.

NB Myalgia can be a sign of myositis, which can transform into Myocarditis therefore cardiac involvement should be excluded.



Interrupt SACT immunotherapy until discussed with Acute Oncology Team. Please contact [on-call oncology/haematology team](#) for advice. Ensure that the patient has monitoring/follow up planned with their oncology/immuno-oncology team.